Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert ...

Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert ...

Rocket Pharmaceuticals announced enrollment completion for phase 2 study using its gene therapy RP-A501 for treatment of male ...

GC Therapeutics claims it can create off-the-shelf therapies from induced pluripotent stem cells faster and simpler than current methods.

It’s been almost a year since the Food and Drug Administration approved the first genetic treatments for sickle cell disease.

The study represents a significant milestone in the field of CAR-T cell therapy for solid tumors, with particular focus on metastatic colorectal cancer (mCRC). The published results highlight the ...

The findings, published in Nature Immunology, indicate that tumors edit the activity of multiple genes to avoid immune ...

Picking a growth stock ... therapy treats sickle cell disease and transfusion-dependent beta thalassemia. Both are rare, ...

gene editing, cell engineering and machine learning to overcome the development and scaling complexities associated with cell therapy and improve patient access across a broad range of disease areas.

Immunosuppressants used in adeno-associated virus (AAV) gene therapy for monogenic disorders present an adverse effect ...

Ori Biotech (Ori), a leader in cell and gene therapy (CGT) manufacturing enabling technology, and Charles River Laboratories (Charles River), a global industry-leading drug discovery, preclinical ...

Analysts at Precedence Research expect the gene-editing market to grow 15.7% annually and reach $29.9 billion by 2032, ...